title: Itraconazole (Sporanox®) for vulvovaginal candidiasis.
abstract: Vulvovaginal candidiasis is a common occurrence among women over 25 years of age. The likelihood of developing infection increases with pregnancy, the use of oral contraceptives or antibiotics, or immune disorders. However, in many cases, the etiology of the disorder is unknown. Sobel1 suggests that some cases of reinfection may actually be cases of relapse, due to either inadequate testing methods, which result in false-negative results after treatment, or to ineffective treatments. Misdiagnosis of the causative organism may also result in ineffective treatment. The most common causal Candida species is C. albicans. However, other, less easily eradicated species may also be involved.
authors.affiliation: Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center (Sunnybrook site) and the University of Toronto, Toronto, Canada.
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
authors.forename: R
authors.initials: R
authors.lastname: Bluhm
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole